Polymer microdepots delivered full-spectrum cannabis extract over two weeks and reduced seizures in mice
Implantable polymer microdepots provided sustained release of multiple phytocannabinoids from a CBD-rich cannabis extract for over 14 days in mice and reduced seizure severity.
Quick Facts
What This Study Found
Subcutaneously injected microdepots released CBD and other phytocannabinoids over 14+ days, maintaining elevated serum levels. One week after a single administration, microdepots reduced tonic-clonic seizure incidence by 40%, increased survival by 50%, and delayed seizure onset by 170% compared to a single extract injection.
Key Numbers
Sustained release over 14+ days. At one week: 40% reduction in tonic-clonic seizure incidence, 50% increase in survival rate, 170% increase in latency to first seizure.
How They Did This
Melt-printed polymeric microdepots encapsulating CBD-rich full-spectrum cannabis extract were injected subcutaneously in mice. Serum phytocannabinoid levels were tracked over time. Efficacy was tested in a pentylenetetrazol-induced seizure model comparing microdepots vs. single extract injection.
Why This Research Matters
Current cannabis administration through oral or inhaled routes has variable absorption and short duration. A long-acting delivery system could provide more consistent therapeutic levels and better seizure control.
The Bigger Picture
Drug delivery technology applied to cannabis could overcome some of the biggest limitations of current medical cannabis use: inconsistent dosing, variable bioavailability, and the need for frequent administration.
What This Study Doesn't Tell Us
Animal study in a chemically induced seizure model, which differs from human epilepsy. Subcutaneous implantation may not be acceptable to all patients. Long-term biocompatibility of the polymer was not assessed.
Questions This Raises
- ?Would these microdepots work similarly in humans?
- ?Could the technology be adapted for other cannabinoid formulations or conditions?
- ?What would the optimal release duration be for clinical use?
Trust & Context
- Key Stat:
- 170% longer time to first seizure with sustained-release microdepots
- Evidence Grade:
- Preclinical proof-of-concept study in mice. Novel delivery technology with promising results but no human data.
- Study Age:
- 2020 study. Early-stage drug delivery research that could inform future clinical formulations of cannabis-based medicines.
- Original Title:
- Full-Spectrum Cannabis Extract Microdepots Support Controlled Release of Multiple Phytocannabinoids for Extended Therapeutic Effect.
- Published In:
- ACS applied materials & interfaces, 12(21), 23707-23716 (2020)
- Authors:
- Uziel, Almog, Gelfand, Anat(2), Amsalem, Keren, Berman, Paula, Lewitus, Gil M, Meiri, David, Lewitus, Dan Y
- Database ID:
- RTHC-02888
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What are microdepots?
Microdepots are tiny polymer structures that slowly release encapsulated drugs over an extended period. In this study, they were injected under the skin and released cannabis extract components for over two weeks.
Why use full-spectrum extract instead of pure CBD?
Full-spectrum extracts contain multiple cannabinoids in specific ratios, which some research suggests may provide enhanced therapeutic effects compared to isolated compounds, sometimes called the "entourage effect."
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02888APA
Uziel, Almog; Gelfand, Anat; Amsalem, Keren; Berman, Paula; Lewitus, Gil M; Meiri, David; Lewitus, Dan Y. (2020). Full-Spectrum Cannabis Extract Microdepots Support Controlled Release of Multiple Phytocannabinoids for Extended Therapeutic Effect.. ACS applied materials & interfaces, 12(21), 23707-23716. https://doi.org/10.1021/acsami.0c04435
MLA
Uziel, Almog, et al. "Full-Spectrum Cannabis Extract Microdepots Support Controlled Release of Multiple Phytocannabinoids for Extended Therapeutic Effect.." ACS applied materials & interfaces, 2020. https://doi.org/10.1021/acsami.0c04435
RethinkTHC
RethinkTHC Research Database. "Full-Spectrum Cannabis Extract Microdepots Support Controlle..." RTHC-02888. Retrieved from https://rethinkthc.com/research/uziel-2020-fullspectrum-cannabis-extract-microdepots
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.